Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: 3 out of 5

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Results 1 - 12 of 12

Recs

0
Member Avatar TerryFool (< 20) Submitted: 3/25/2014 5:50:51 AM : Outperform Start Price: $3.59 CYCC Score: -20.49

BUY@ 3.6 TP 10

Recs

0
Member Avatar TerryHoodSr (34.74) Submitted: 3/24/2014 6:50:19 PM : Outperform Start Price: $3.69 CYCC Score: -22.82

SPEC BUY@ 3.7 TP 10

Recs

0
Member Avatar UnstableEnabled (< 20) Submitted: 12/21/2013 3:30:17 AM : Outperform Start Price: $3.85 CYCC Score: -28.18

A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.

It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.

Sorely depressed, any good new will cause the stock to surge upward.

Recs

0
Member Avatar dunloggin (74.44) Submitted: 11/7/2013 5:55:56 PM : Outperform Start Price: $3.56 CYCC Score: -26.31

More of a short term hold, news about some patents that interested me.

Recs

3
Member Avatar zzlangerhans (99.70) Submitted: 4/18/2013 12:44:13 AM : Outperform Start Price: $4.95 CYCC Score: -65.16

Cyclacel is a swamp with a lot of traders' skeletons floating in the muck. The price chart since inception should tell you to approach the stock gingerly, if at all. I've already been burned once, but thankfully escaped with a small loss after ditching the hot potato close to the peak in 2012. That spike came thanks to some nimbly spun data from uninspiring DNA synthesis inhibitor sapacitabine.

While there are some midstage trials of sapacitabine in progress and CDK inhibitor seliciclib hasn't been officially put out to pasture, the only real hope for Cyclacel lies in the outcome of the SEAMLESS phase III trial of sapacitabine in elderly AML. At some point traders are going to start seeing Cyclacel as cheap at a 50M cap with a phase III cancer trial in progress, but given that the trial has only enrolled a third of the necessary 500 patients after more than two years it is likely still too early to risk a real investment. Meanwhile, the contamination of the capital structure with preferred stock and a history of unimpressive sapacitabine performance in midstage trials should provide further incentive to seek better opportunities for real life investments until SEAMLESS is closer to a binary catalyst.

Recs

0
Member Avatar toegar2000 (49.31) Submitted: 3/2/2013 10:25:20 AM : Outperform Start Price: $5.50 CYCC Score: -74.16

Looks good IMO

Recs

0
Member Avatar stainsolution (35.78) Submitted: 4/9/2012 9:52:19 AM : Outperform Start Price: $4.55 CYCC Score: -75.47

Small Cancer/Bio

Recs

0
Member Avatar RBuskey106 (40.02) Submitted: 3/21/2012 8:23:14 PM : Outperform Start Price: $4.40 CYCC Score: -70.41

Small cancer bio

Recs

0
Member Avatar nwarrior (< 20) Submitted: 7/27/2011 2:55:42 AM : Outperform Start Price: $8.26 CYCC Score: -111.77

This stock is poised to rise, already near it's 52 Week low. With a high insider net holding volume and low debt, this is an investment with great potential.

Recs

0
Member Avatar rwaddoups (< 20) Submitted: 1/3/2011 1:22:52 PM : Outperform Start Price: $10.50 CYCC Score: -125.85

yes

Recs

0
Member Avatar verbatum (< 20) Submitted: 10/5/2010 8:03:18 PM : Outperform Start Price: $11.34 CYCC Score: -143.24

Great Pipeline,Great PHASE II, Entering PHASE III, Shelf registered, Orphan Designation

Recs

0
Member Avatar imrhh (< 20) Submitted: 5/5/2007 11:23:19 PM : Underperform Start Price: $54.60 CYCC Score: +132.94

This is one of Zack's #1 rated stocks. I do not understand their reasoning for this though. The chart that came up on my computer showed this stock starting at around zero and then going on a very steady decline to at least minus 100%. Call me crazy, but I can't see much of a future in this stock unless it is bought by one of the bigger companies.

Results 1 - 12 of 12

Featured Broker Partners


Advertisement